File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Trends in asthma therapy in Hong Kong, 1987-1992

TitleTrends in asthma therapy in Hong Kong, 1987-1992
Authors
Issue Date1993
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/02770903.asp
Citation
Journal Of Asthma, 1993, v. 30 n. 6, p. 475-483 How to Cite?
AbstractTo audit the clinical practice in drug treatment of bronchial asthma in Hong Kong, two questionnaire surveys were conducted in 1987 and 1992. The questionnaire was adapted from the 1984 European Audit. The response rate was 40% (248 of 615 mailings) in 1987 and 32% (207 of 652 mailings) in 1992. A total of 86% and 87% of responders were general practitioners (GP), respectively, and the others were chest physicians (CP). For treatment of acute severe asthma in adults, parenteral aminophylline was the first drug used by GP in 1987, whereas inhaled β-agonist was used in 1992. Parenteral steroid was more often used by both GP and CP in 1992. In children, inhaled β-agonist was always the first choice and parenteral steroid ranked higher in 1992, overtaking parenteral aminophylline. For maintenance therapy of chronic asthma in adults, inhaled β-agonist ranked first in both surveys. Inhaled steroid has become much more popular with GP, ranking second in 1992, overtaking oral bronchodilators. With CP, inhaled steroid was already ranking second in 1987, and it was used as the first drug, as frequently as inhaled β-agonist, in 1992. In children, in 1987, inhaled β-agonist was the first drug of choice, and prophylactic drugs ranked lower than oral bronchodilators with both GP and CP. In 1992, cromoglycate and inhaled steroids were much more often used, so much so that among CP, inhaled steroid ranked first, just ahead of inhaled β-agonist. The dose of metered-dose β-agonist most commonly recommended by both GP and CP was 5-10 puffs per day in both 1987 and 1992, but there was a trend to recommend less (0-5 puffs) by CP in 1992. Powder inhalers were more widely used by GP in 1992. Hyposensitization was not commonly practiced, but there was an increase in its use in 1992. In summary, there has been a change in therapeutic attitudes among doctors in Hong Kong over the survey interval of 4 1/4 years. Anti-inflammatory drugs and the inhalational route of administration are used much more often now, even among primary care physicians, in keeping with international recommendations.
Persistent Identifierhttp://hdl.handle.net/10722/162019
ISSN
2015 Impact Factor: 1.854
2015 SCImago Journal Rankings: 0.762
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorIp, MSMen_US
dc.contributor.authorSo, SYen_US
dc.contributor.authorLam, CLKen_US
dc.contributor.authorLam, WKen_US
dc.contributor.authorChan, JCKen_US
dc.contributor.authorTse, MHWen_US
dc.date.accessioned2012-09-05T05:16:42Z-
dc.date.available2012-09-05T05:16:42Z-
dc.date.issued1993en_US
dc.identifier.citationJournal Of Asthma, 1993, v. 30 n. 6, p. 475-483en_US
dc.identifier.issn0277-0903en_US
dc.identifier.urihttp://hdl.handle.net/10722/162019-
dc.description.abstractTo audit the clinical practice in drug treatment of bronchial asthma in Hong Kong, two questionnaire surveys were conducted in 1987 and 1992. The questionnaire was adapted from the 1984 European Audit. The response rate was 40% (248 of 615 mailings) in 1987 and 32% (207 of 652 mailings) in 1992. A total of 86% and 87% of responders were general practitioners (GP), respectively, and the others were chest physicians (CP). For treatment of acute severe asthma in adults, parenteral aminophylline was the first drug used by GP in 1987, whereas inhaled β-agonist was used in 1992. Parenteral steroid was more often used by both GP and CP in 1992. In children, inhaled β-agonist was always the first choice and parenteral steroid ranked higher in 1992, overtaking parenteral aminophylline. For maintenance therapy of chronic asthma in adults, inhaled β-agonist ranked first in both surveys. Inhaled steroid has become much more popular with GP, ranking second in 1992, overtaking oral bronchodilators. With CP, inhaled steroid was already ranking second in 1987, and it was used as the first drug, as frequently as inhaled β-agonist, in 1992. In children, in 1987, inhaled β-agonist was the first drug of choice, and prophylactic drugs ranked lower than oral bronchodilators with both GP and CP. In 1992, cromoglycate and inhaled steroids were much more often used, so much so that among CP, inhaled steroid ranked first, just ahead of inhaled β-agonist. The dose of metered-dose β-agonist most commonly recommended by both GP and CP was 5-10 puffs per day in both 1987 and 1992, but there was a trend to recommend less (0-5 puffs) by CP in 1992. Powder inhalers were more widely used by GP in 1992. Hyposensitization was not commonly practiced, but there was an increase in its use in 1992. In summary, there has been a change in therapeutic attitudes among doctors in Hong Kong over the survey interval of 4 1/4 years. Anti-inflammatory drugs and the inhalational route of administration are used much more often now, even among primary care physicians, in keeping with international recommendations.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/02770903.aspen_US
dc.relation.ispartofJournal of Asthmaen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdrenergic Beta-Agonists - Therapeutic Useen_US
dc.subject.meshAdulten_US
dc.subject.meshAsthma - Drug Therapyen_US
dc.subject.meshChilden_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshDrug Therapy - Trendsen_US
dc.subject.meshFamily Practiceen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshPulmonary Medicineen_US
dc.subject.meshQuestionnairesen_US
dc.subject.meshSteroids - Therapeutic Useen_US
dc.titleTrends in asthma therapy in Hong Kong, 1987-1992en_US
dc.typeArticleen_US
dc.identifier.emailIp, MSM:msmip@hku.hken_US
dc.identifier.emailLam, CLK:clklam@hku.hken_US
dc.identifier.authorityIp, MSM=rp00347en_US
dc.identifier.authorityLam, CLK=rp00350en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3109/02770909309056757-
dc.identifier.pmid7902346-
dc.identifier.scopuseid_2-s2.0-0027770545en_US
dc.identifier.volume30en_US
dc.identifier.issue6en_US
dc.identifier.spage475en_US
dc.identifier.epage483en_US
dc.identifier.isiWOS:A1993MZ75700008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridIp, MSM=7102423259en_US
dc.identifier.scopusauthoridSo, SY=7102397816en_US
dc.identifier.scopusauthoridLam, CLK=24755913900en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridChan, JCK=23090202000en_US
dc.identifier.scopusauthoridTse, MHW=7103352612en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats